The tumor necrosis factor family and correlation with disease activity and response to treatment in hairy cell leukemia

European Journal of Haematology

Volumn 62, Issue 2, 1999, Pages 71-75

  Barak, Vivian ^a   Nisman, Benjamin ^a   Polliack, Aaron ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

2 CDA; HCL; Response; STNF R60; sTNF R80; TNF

Indexed keywords

ALPHA INTERFERON; CLADRIBINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; B CELL LEUKEMIA; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; DISEASE ACTIVITY; HAIRY CELL LEUKEMIA; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0032956309     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1999.tb01724.x     Document Type: Article

References (41)

1. BURKE JS, BYRNE GE, RAPAPORORT H. Hairy cell leukemia (leukemic reticuloendotheliosis). A clinical study of 21 patients. Cancer 1974;33:1399-1410.
2. BOURONCLE BA, WISEMAN BK, DOAN CA. Leukemic reticuloendotheliosis. Blood 1958;13:609.
3. TILI KJ, CAWLEY JC. Accessory cells mediate hairy-cell proliferation by mechanism(s) involving both adhesion and TNF alpha secretion. Br J Haematol 1994;87:687-694.
4. SCHULER M, HUBER C, PESCHEL C. Cytokines in the pathophysiology and treatment of chronic B-cell malignancies. A review. Ann Hematol 1995;71:57-63.
5. CORDINGLEY FT, BIANCHI A, HOFFBRAND AV, et al. Tumour necrosis factor as an autocrine tumour growth factor for chronic B-cell malignancies. Lancet 1988;1:969-971.
6. HASSAN IB, LANTZ M, SUNDSTROM C. Effect of alpha-IFN on cytokine-induced antigen expression and secretion of TNF, LT and IgM in HCL. Leuk Res 1991;15:903-910.
7. BUCK C, DIGEL W, SCHONIGER W, et al. Tumor necrosis factor-alpha, but not lymphotoxin, stimulates growth of tumor cells in hairy, cell leukemia. Leukemia 1990;4:431-434.
8. FOA R, MASSAIA M, CARDONA S, et al. Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: a possible regulatory role of TNF in the progression of the disease. Blood 1990;76:393-400.
9. JANCKILA AJ, GENTILE PS, YAM LT. Hemopoietic inhibition in hairy cell leukemia. Am J Hematol 1991;38:30-39.
10. TANIGUCHI N, KURATSUNE H, KANAMARU A, et al. Inhibition against CFU-C and CFU-E colony formation by soluble factor(s) derived from hairy cells. Blood 1989;73:907-913.
11. HEILIG B, MAPARA M, BROCKHAUS M, KRAUTH K, DORKEN B. Two types of TNF receptors are expressed on human normal and malignant B lymphocytes. Clin Immunol Immunopathol 1991;61:260-267.
12. FOA R, GUARINI A, FRANCIA DI CELLE P, et al. Constitutive production of tumor necrosis factor-alpha in hairy cell leukemia: possible role in the pathogenesis of the cytopenia(s) and effect of treatment with interferon-alpha. J Clin Oncol 1992;10:954-959.
13. DIGEL W, PORZSOLT F, SCHMID M, HERRMANN F, ESSLAUER W, BROCKHAUS M. High levels of circulating soluble receptors for tumor necrosis factor in hairy cell leukemia and type B chronic lymphocytic leukemia. J Clin Invest 1992;89:1690-1694.
14. TRENTIN L, ZAMBELLO R, AGOSTINI C, et al. Expression and functional role of tumor necrosis factor receptors on leukemic cells from patients with type B chronic lymphoproliferative disorders. Blood 1993;81:752-758.
15. SCHILLER JH, BITTNER G, SPRIGGS DR. Tumor necrosis factor, but not other hematopoietic growth factors, prolongs the survival of hairy cell leukemia cells. Leuk Res 1992;16:337-346.
16. TRENTIN L, ZAMBELLO R, PIZZOLO G, et al. Tumor necrosis factor-alpha and B-cell growth factor induce leukemic hairy cells to proliferate in vitro. Cancer Detect Prevent 1991;15:385-390.
17. HUANG D, REITTIE JE, STEPHENS S, HOFFBRAND AV, BRENNER MK. Effects of anti-TNF monoclonal antibody infusion in patients with hairy cell leukaemia. Br J Haematol 1992;8:231-234.
18. LAURIA F, RASPADORI D, BENFENATI D, RONDELLI D, PALLOTTI A, TURA S. Biological markers and minimal residual disease in hairy, cell leukemia. Leukemia 1992;6(suppl 4):149-151.
19. ROMQUIN N, BILLARD C. Autocrine loop of tumor necrosis factor induced by interferon-alpha in tumor cells from hairy cell leukemia. Leukemia 1995;9:87-94.
20. SCHMID M, PORZSOLT F. Autocrine and paracrine regulation of neoplastic cell growth in hairy cell leukemia. Leuk Lymph 1995;17:401-410.
21. SCHMID M, SCHREZENMEIER H, STAIB G, PORZSOLT F. Evidence for a paracrine pathway of B-cell stimulation in hairy cell leukaemia. Br J Haematol 1995;90:156-162.
22. DE TOTERO D, CARBONE, A, TAZZARI PL, et al. Expression of IL-2 receptor alpha, beta and gamma chains in hairy cell leukemia. Lymphoma 1994;14(suppl 1):27-32.
23. SEMENZATO G, TRENTIN L, ZAMBELLO R, et al. Origin of the soluble interleukin-2 receptor in the serum of patients with hairy cell leukemia. Leukemia 1988;2:788-792.
24. BARAK V, GINZBURG M, KALICKMAN I, POLLIACK A. Serum soluble IL-2 receptor levels are associated with clinical disease status and histopathological grade in non-Hodgkin's lymphoma. Leuk Lymph 1992;7:431-438.
25. BARAK V, NISMAN B, DANN E, et al. Serum Interleukin 1Β levels as a marker in hairy cell leukemia: correlation with disease status and sIL-2R levels. Leuk Lymph 1994;14:33-39.
26. BARAK V, NISMAN B, POLLIACK A, VANNIER E, DINARELLLO CA. Correlations of serum levels of interleukin-1 family members with disease activity and response to treatment in hairy cell leukemia. Eur Cytokine Netw 1998;9:33-39.
27. BIANCHI AC, HESLOP HE, DREXLER HG, et al. Effects of tumour necrosis factor and alpha interferon on chronic B cell malignancies. Nouv Rev Fr Hematol 1988;30:317-319.
28. ANNINO L, FERRARI A, GIONA F, et al. Deoxycoformycin induces long-lasting remissions in hairy cell leukemia: clinical and biological results of two different regimens. Leuk Lymph 1994;14(suppl 1):115-119.
29. PIRO LD, CARRERA CJ, CARSON DA, BEUTLER E. Lasting remissions in hairy cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 1990;322:1117-1121.
30. PIRO LD. 2-chlorodeoxyadenosine treatment of lymphoid malignancies. Blood 1992;79:843-845.
31. DANN EJ, GILLIS EA, BARAK V, et al. Hairy cell leukemia: Results of 2-chlorodeoxyadenosine therapy in Jerusalem. Leuk Lymph 1994;14(suppl 1):127-132.
32. TALLMAN MS, HAKIMIAN D, DYRDA S, KILEY C, NEMCEK A, PETERSON L. Asessment of complete remission after 2-chlorodeoxyadenosine for hairy cell leukemia: utility of marrow immunostaining and measurement of splenic index. Leuk Lymph 1994;14(suppl 1):133-138.
33. TALLMAN MS, HAKIMIAN D, VARIAKOJIS D, et al. A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood 1992;80:2203-2209.
34. COHEN J, COHEN P. Applied multiple regression/correlation analysis for the behavioral sciences. Hillsdale, NJ: Lawrence Erlbaum Associates 1983:172-173.
35. JULIUSSON G, LILIEMARK J. Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-CDA: relation to opportunistic infections. Blood 1992;79:888-894.
36. BARAK V, NISMAN B, VANNIER E, DINARELLO CA, POLIACK A. IL-1 family members and TNF in HCL (abstract). Blood 1996;88:242a.
37. WILSON AG, DE VRIES N, POCIOT E, DI GIOVINE ES, VAN DER PUTTE, LBA, DUFF GW. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8 and DR3 alleles. J Exp Med 1993;177:577-580.
38. DEMETER J, PORZSOLT F, RÄMISCH S, SCHMID M, MESSER G. Polymorphism of the tumour necrosis factor-alpha and lymphotoxin-alpha gnes in hairy cell leukaemia. Br J Haematol 1997;97:132-134.
39. WHICHER JT, BANKS RE. Cytokines as tumor markers. Scand J Clin Lab Invest 1995;55(suppl 221):122-144.
40. BARAK V. Cytokine receptors in disease. Israeli J Med Sci 1995;31:1-9.
41. MICHIEL, DF, OPPENHEIM JJ. Cytokines as positive and negative regulators of tumor promotion and progression. Semin Cancer Biol 1992;3:3-15.